Index Entries

Leora R. Feldstein, Jasmine Ruffin, Ryan Wiegand, Lauren Grant, Tara M. Babu, Melissa Briggs-Hagen, Jefferey L. Burgess, Alberto J. Caban-Martinez, Helen Y. Chu, Katherine D. Ellingson, Janet A. Englund, Kurt T. Hegmann, Zuha Jeddy, Jennifer Kuntz, Adam S. Lauring, Karen Lutrick, Emily T. Martin, Clare Mathenge, Jennifer Meece, Claire M. Midgley, Arnold S. Monto, Allison L. Naleway, Gabriella Newes-Adeyi, Leah Odame-Bamfo, Lauren E. W. Olsho, Andrew L. Phillips, Ramona P. Rai, Sharon Saydah, Ning Smith, Harmony Tyner, Molly Vaughan, Ana A. Weil, Sarang K. Yoon, Amadea Britton, and Manjusha Gaglani
December 5, 2024
Journal of the Pediatric Infectious Diseases Society
National Center for Immunization and Respiratory Diseases (CDC)

"Abstract

To understand how coronavirus disease 2019 vaccines impact infection risk in children <5 years, we assessed risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from September 2022 to April 2023 in 3 cohort studies. There was no difference in risk by vaccination status. While vaccines reduce severe disease, they may not reduce SARS-CoV-2 infections in young children...

Results

... There was no difference in risk of infection or symptomatic COVID-19 by vaccination status alone, regardless of timing of vaccination or manufacturer type. However, naïve participants vaccinated with Pfizer-BioNTech were more likely to be infected and experience symptomatic COVID-19 compared to naïve and unvaccinated participants (HR: 2.59 [95% CI: 1.27–5.28]), whereas participants with evidence of prior infection and who were vaccinated with Pfizer-BioNTech were less likely to be infected (HR: 0.22 [95% CI: 0.05–0.95])."

document
breakthrough cases,COVID-19,natural immunity,vaccines